
cAMPfield Therapeutics Shakes Up Leadership to Accelerate IBD Drug Program
San Diego-based cAMPfield Therapeutics has overhauled its senior executive team, appointing four industry veterans to spearhead the development of its lead drug candidate, prifemilast. The move marks a strategic push to transition the oral PDE4 inhibitor into global Phase 2 trials for ulcerative colitis and Crohn’s disease.

























